Quindós Guillermo, Ruesga María Teresa, Martín-Mazuelos Estrella, Salesa Ricardo, Alonso-Vargas Rocío, Carrillo-Muñoz Alfonso Javier, Brena Sonia, San Millán Rosario, Pontón José
Departamento de Inmunología, Microbiología y Parasitología, Facultad de Medicina y odontología, Universidad del País Vasco, Bilbao, Spain.
Rev Iberoam Micol. 2004 Jun;21(2):63-9.
The aim of this study was to determine the prevalence of primary resistance to 5-fluorocytosine (5FC) among clinical isolates of yeasts in Spain where this drug is not currently available for therapy. We have tested the in vitro activity of 5FC against 1,021 recent yeast clinical isolates, including 522 Candida albicans, 140 Candida parapsilosis, 68 Candida glabrata, 41 Candida dubliniensis, 50 Candida guilliermondii, 34 Candida tropicalis, 28 Candida krusei, 20 Candida famata, 11 Cryptococcus neoformans, 5 Cryptococcus albidus, 43 Rhodotorula spp., 24 Trichosporon spp., 5 Saccharomyces cerevisiae, 9 Pichia spp., and 21 isolates from other 11 yeast species. The MICs were determined by the ATB Fungus agar microdilution test (bioMerieux, France) and the following interpretive breakpoints were used: susceptible, > 4 microg/ml; intermediate, 8 to 16 microg/ml; resistant, > 32 microg/ml. 5FC was very active against Candida spp. and other medically important yeasts as 852 (83.4%) of the studied isolates were susceptible (MIC < 4 microg/ml). The species most susceptible to 5FC were C. dubliniensis (100%of isolates; MIC90, 0.25 microg/ml), C. famata (100% of isolates; MIC90, 0.25 microg/ml), C. guilliermondii (98%of isolates; MIC90, 0.25 microg/ml), C. glabrata (95.5% of isolates; MIC90, 0.25 microg/ml), and C. neoformans (90.9% of isolates; MIC90, 2 microg/ml). Primary resistance to 5FC was very uncommon, and a MIC > 32 microg/ml, indicator of in vitro resistance, was observed in 106 isolates (10.4%): 77 C. albicans (16.5% of isolates; MIC90, > 128 microg/ml), 9 C. parapsilosis (6.4% of isolates; MIC90, 8 microg/ml), 4 C. albidus (80% of isolates, MIC50, > 128 microg/ml), 3 C. glabrata (4.4% of isolates; MIC90, 0.25 microg/ml), 3 C. tropicalis (8.8% of isolates; MIC90, 4 microg/ml), 2 C. krusei (7.1% of isolates; MIC90, 8 microg/ml), 2 Rhodotorula spp. (4.6% of isolates, MIC90, 1 microg/ml), 8 Trichosporon spp. (33.3% of isolates; MIC90, 64 microg/ml), and 1 C. lipolytica (50% of isolates). Interestingly, most C. albicans (67 out of 77 isolates) resistant to 5FC were serotype B isolates.
本研究的目的是确定在西班牙目前尚无5-氟胞嘧啶(5FC)用于治疗的情况下,酵母临床分离株中对5FC的原发性耐药率。我们检测了5FC对1021株近期酵母临床分离株的体外活性,这些分离株包括522株白色念珠菌、140株近平滑念珠菌、68株光滑念珠菌、41株都柏林念珠菌、50株季也蒙念珠菌、34株热带念珠菌、28株克鲁斯念珠菌、20株法塔念珠菌、11株新生隐球菌、5株浅白隐球菌、43株红酵母属、24株丝孢酵母属、5株酿酒酵母、9株毕赤酵母属以及来自其他11种酵母的21株分离株。通过ATB真菌琼脂微量稀释试验(法国生物梅里埃公司)测定最低抑菌浓度(MIC),并采用以下解释性断点:敏感,>4μg/ml;中介,8至16μg/ml;耐药,>32μg/ml。5FC对念珠菌属和其他医学上重要的酵母具有很高的活性,因为852株(83.4%)研究分离株对其敏感(MIC<4μg/ml)。对5FC最敏感的菌种是都柏林念珠菌(100%的分离株;MIC90,0.25μg/ml)、法塔念珠菌(100%的分离株;MIC90,0.25μg/ml)、季也蒙念珠菌(98%的分离株;MIC90,0.25μg/ml)、光滑念珠菌(95.5%的分离株;MIC90,0.25μg/ml)和新生隐球菌(90.9%的分离株;MIC90,2μg/ml)。对5FC的原发性耐药非常罕见,在106株分离株(10.4%)中观察到MIC>32μg/ml(体外耐药指标):77株白色念珠菌(占分离株的16.5%;MIC90,>128μg/ml)、9株近平滑念珠菌(占分离株的6.4%;MIC90,8μg/ml)、4株浅白隐球菌(80%的分离株,MIC50,>128μg/ml)、3株光滑念珠菌(占分离株的4.4%;MIC90,0.25μg/ml)